2月10日 - ** 美国癌症诊断公司PersonalisPSNL.O股价盘前上涨2.3%至8.01美元
** 该公司称， (link) 医疗保险现在将支付其用于监测早期非小细胞肺癌（最常见的肺癌）的NeXT Personal测试费用。
** 该公司称，该检验可追踪血液中微小的循环肿瘤DNA(ctDNA)，这些DNA可提示癌症的存在；该检验可分析数百种肿瘤特异性突变，以指导持续的治疗决策。
** 该公司称，医疗保险（Medicare）继批准对乳腺癌患者进行同样的检测后又采取了这一举措。
** 医疗保险（Medicare）是美国政府为 65 岁及以上老年人提供的医疗保险计划。
** 2025 年股价上涨约 38%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.